Public health, cardiovascular disease and molecular biology  by Harrap, Stephen B.
Kidney International, Vol. 46 (1994), pp. 1546—1549
GENETICS AND MOLECULAR BIOLOGY
Public health, cardiovascular disease and molecular biology
STEPHEN B. HARRAP
Department of Social & Preventive Medicine, Monash Medical School, Alfred Hospital, Prahran, Victoria, Australia
Public health, cardiovascular disease and molecular biology. Rapid devel-
opments in molecular biology provide the tools to search for genetic markers
of coronary heart disease. Already the angiotensin converting enzyme and the
angiotensinogen genes have been implicated in myocardial infarction and
hypertension. However, common conditions such as coronary disease raise
special problems for genetics both in selection of suitable subjects and the use
of informative genetic methods, Traditionally genetics has focused on the
fan'iily; now it must broaden that view to identify markers that are relevant to
the general community. The magnitude and complexity of the problem
demands collaboration between epidemiologists, physicians, geneticists and
laboratory scientists. This paper proposes a two stage approach to the genetics
of coronary heart disease, beginning with affected relative pair linkage studies
using the new generation gene maps to define chromosomal regions of
interest. The thorough and systematic search using gene maps also offers the
possibility of defining genetic markers of "hidden" coronaiy risk factors, In
the second stage, candidate genes within these regions are examined in
case-control association studies to identify simple markers that divide the
population into groups with contrasting risk of coronary disease. It is
important that families and cases are representative of the general popula-
tion, otherwise the predictive value of the new genetic markers will be in
doubt, In particular, genetic analyses should avoid the potential bias resulting
from the exclusion of cases of sudden and unexpected coronary death.
The challenge
Genes associated with the renin-angiotensin system have re-
cently been associated with coronary heart disease (CHD) and its
risk factors. A variant of the angiotensin converting enzyme gene
was found to be more frequent in cases of myocardial infarction
[1], and the angiotensinogen gene appears to be linked to
hypertension [2]. These developments reflect the potential con-
tribution of molecular biology to the understanding of human
disease. However, the greatest challenge for the new technology is
to bring tangible benefits to public health, in particular common
disease such as CHD which remains the single most common
cause of death in Australia [3].
Accessible molecular biology and the enormous number of
DNA markers will result in an exponential growth in genetic
studies. There is, however, considerable variation in the popula-
tions studied, research strategies and sampling methods. This
paper examines these issues in light of the overriding need to
produce results that are useful for the prevention and treatment
of CHD in the general community.
Changes in community environment and lifestyle have contrib-
uted to the decline in coronary mortality rates [4] but have led to
a situation where genetic causes assume increasing importance.
Genes govern individual susceptibility to disease [5, 6], and CHD
itself, the underlying processes of atherosclerosis, coagulation and
the associated risk factors, high blood pressure and hypercholes-
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terolemia, all show a strong familial [7] and genetic [8, 9] tend-
encies.
The genetics of known risk factors is an important area of
research. However, although existing risk factors are associated
with many cases of CHD [10], the majority have low or moderate
risk by existing criteria [5]. Applied to the Western nations, the
risk of coronary disease remains "hidden" in one sixth of the
entire population until manifest as sudden death or myocardial
infarction. Clearly present risk assessment is inadequate and, as a
consequence, prevention is suboptimum. Genetics may be impor-
tant in improving overall risk assessment.
Biological variability of risk factors may explain why some
individuals with apparently low risk die of coronary disease, but
the significant shortfall may reflect the influence of unidentified
risk factors. Family history is a well-recognized, independent
coronary risk factor [11—14] but is not sufficiently precise [15].
New strategies must be developed to define risk more accurately,
and it may be possible to demonstrate, among individuals at
moderate or low risk by present criteria, that CHD is associated
with certain genetic characteristics not found in high risk individ-
uals who do not develop coronary disease.
The potential
New genetic markers have many potential benefits [3]. In contrast
to risk factors such as hypertension and hypercholesterolemia which
are often not evident until middle age, inherent genetic risk is
measurable at all ages. Simple advice regarding lifestyle can be
provided to young adults before the development of irreversible
coronary atherosclerosis. Because genetic tests are qualitative, they
are not prone to errors associated with biological variability. New
genetic tests would also complement existing risk factor assessment.
At present 10 to 15% of the middle-aged to elderly population with
elevated blood pressure are eligible for hypotensive treatment,
mainly with drug therapy. A similar percentage of the population
may soon be receiving drug treatment for the reduction of elevated
plasma lipids. The benefit from such therapy has been lower than
expected, partly because of misclassification of individuals as hyper-
tensive or hypercholesterolemic [16], but also because only a minor-
ity of such individuals develop clinical disease. The majority of
patients receiving therapy undergo unnecessary treatment, with its
attendant costs, risks and adverse effects on quality of life. Genetic
markers may be used to target drug treatment at the hypertensive
and hypercholesterolemic patients who are most likely to develop
cardiovascular complications.
The contribution of genetics may not be limited to the identi-
fication of genes responsible for increased susceptibility. Im-
proved understanding of the molecular basis of coronary risk may
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also reveal something of .the underlying pathophysiological pro-
cesses and facilitate the development of new preventive strategies.
Despite these enticing prospects, progress in the molecular
genetics of coronary risk has been patchy. One important reason
is that laboratory expertise does not translate easily to the
preventive epidemiology of coronary disease. Traditionally genet-
ics has focused on rare disease within families rather than
common conditions in the general community. Precision in mo-
lecular measurements cannot compensate for imprecision in
epidemiological research design. The magnitude and complexity
of the challenge demands new forms of collaboration between
epidemiologists, geneticists and laboratory scientists. Large well-
designed multidisciplinary studies are essential.
A strategy
A summary of the strategy is shown in Figure 1.
Stage I—Family studies
The first step begins with families to determine linkage between
particular chromosomal regions and CHD. Classical family stud-
ies involving large multigenerational pedigrees are not suited to
the study of CHD. Pedigrees selected for their high incidence of
CHD are by their very nature unusual. Within pedigrees, disease
classification must be entirely accurate and unambiguous, which is
not possible for CHD. The inclusion of family members who are
asymptomatic, yet have significant coronary artery disease intro-
duces significant confounding.
The "affected relative pairs" method [17, 18] is an attractive
alternative that requires the recruitment of families in which two
or more relatives have suffered myocardial infarction. Such fam-
ilies are not uncommon and, therefore, more representative. The
approach requires only one generation if the relatives are siblings,
and it also avoids the false negative family members who are
predisposed but asymptomatic at screening. The basis of the
method is to define gene markers that are shared by affected
relatives more often than expected by chance. This will occur if
the gene marker is linked closely to the causative gene.
Candidate genes such as the ACE and angiotensinogen genes
can be used in this way, but gene maps offer a comprehensive and
systematic analysis of the entire genome [19, 20]. They are
particularly suited to CHD in which several genes are believed to
contribute to predisposition. Importantly, they offer the potential
to reveal the chromosomal map references of both recognized and
"hidden" risk factors. This is an important advantage over studies
in which candidate genes address only a very small portion of the
genome and are chosen according to preconceived notions of risk
mechanisms, which by definition ignores "hidden" risk factors.
The detection of genetic markers for a disease with a complex
mode of inheritance such as coronary artery disease depends on a
number of factors such as the statistical power of the study, the
contribution of the suspected locus to the disease, the genetic
heterogeneity of the disease (number of implicated loci, respec-
tive effects of each locus, loci interactions) and the proximity of
the marker and the disease gene. These variables make accurate
calculations of sample size difficult, but theoretical [21] and
empirical observations [2] suggest that between 100 and 200
relative pairs should be sufficient.
Fig. 1. A simplified two stage strategy for the identification of genetic markers
of coronaPy heart disease (CHD).
Family studies:
Linkage analysis
Affected relative pairs
Gene maps
Highly polymorphic markers
Population studies:
Association analysis
Cases and controls
Fatal and non-fatal CHD
Candidate genes
Less polymorphic markers
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Stage 11—Population studies
Map references from family studies form the basis for the devel-
opment of population markers of CHD risk. The reason for the two
phases is that the polymorphic characteristics of the map markers
that are so useful in family linkage studies limit their utility for the
screening the general population. Highly individual gene map mark-
ers provide distinctive pictures of siblings genetics, but when applied
to a population would divide the community into a relatively large
number of small groups. Useful markers should characterize popu-
lation groups with contrasting predisposition to coronary artery
disease. Less polymorphic markers of candidate genes are likely to be
more suited to this purpose. A logical strategy is to develop restric-
tion fragment length polymorphism (RFLP) markers associated with
candidate genes that lie within the chromosomal regions of interest.
This is a much more focused than simply selecting candidate genes at
random, thus reducing the likely possibilities from many thousands to
tens of gene markers. The frequency of particular candidate geno-
types is then compared between cases and controls. Where the
relative frequency of a genotype is significantly greater in cases than
controls, it is inferred that this marker is a useful indication of
increased risk. It is also desirable to select RFLP that are not so rare
that screening becomes inefficient, nor so common that they are
found in most people.
Careful selection of cases and controls is important to ensure
that markers will be useful in the general population. One
potential bias is the exclusion of cases of sudden and unexpected
death from coronary disease. Sampling of cases tends to be based
on subjects with symptomatic coronary heart disease who reach
medical attention. For example, studies of the angiotensin con-
verting enzyme (ACE) gene were undertaken only in survivors of
myocardial infarction [1]. Such sampling is simple and opportu-
nistic but deficient, in that it does not represent the wide spectrum
of coronary disease in the general community. Those affected by
sudden coronary-related deaths stand to gain the most from
improved population risk assessment. The magnitude of this
problem is substantial. Seventy percent of coronary deaths occur
outside the hospital, and a history of heart disease can be detected
in less than half who die before receiving medical attention [22].
There is no guarantee that the predisposing factors to non-fatal
and fatal coronary disease are identical. For example, death may
follow myocardial infarction in those with special susceptibility to
irregularity of cardiac rhythm. Risk markers of non-fatal CHD
might be irrelevant to the substantial proportion of the commu-
nity predisposed to sudden and unexpected death. It is also
possible that markers defined in survivors might reflect a non-
specific genetic propensity to survive, rather than predisposition
to CHD itself. To ensure that the broad range of significant
coronary disease is represented, cases should be drawn from both
survivors of myocardial infarction and from those dying unexpect-
edly with severe coronary atherosclerosis. This can create logistic
difficulties and emphasizes the need for a multidisciplinary ap-
proach to the genetics of CHD.
The future
The careful integration of public health principles and labora-
tory techniques has the potential to make important contributions
to the early detection and prevention of coronary disease, In the
future, genetic risk assessment may be as routine as measuring
cholesterol today. However, genetic markers will need to be
proven in prospective trials of their predictive value. Potential
differences in genetic composition or environment means that
caution should be exercised in extrapolating results from one
population to another. It is also important from the public health
perspective to ensure that the costs of the new technology does
not outweigh the benefits. The magnitude of this process requires
considerable investment and resources on a scale comparable to
the Framingham studies of coronary risk.
Reprint requests to Dr. S.B. Harrap, Genetic Physiology Unit, Department
of Medicine, Austin Hospital Heidelberg, Victoria 3084, Australia.
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